In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor. PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discussed how CMC review practices are evolving and what that means for manufacturing strategy.
Alfred Rumondor, PhD
Advertisement
Alfred Rumondor, PhD, CMC Support for Due Diligence for External Assets at AbbVie.
Articles by Alfred Rumondor, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
CPHI Milan Names 2026 Pharma Awards Finalists
2
Lilly's $2.875B Merida Deal Has Implications for Autoantibody Diseases
3
AAPS PharmSci 360: Microstructure Intelligence in Predictive Drug Development, Part 1
4
From Phase 1 Screening to Commercial Strategy: Selecting the Right Amorphous Solid Dispersion Technology Early
5